895
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor: Clinical Oncology

The optimal neoadjuvant chemotherapy regime for muscle-invasive bladder cancer: still an open question?

ORCID Icon, , &
Pages 1515-1516 | Received 18 Aug 2022, Accepted 09 Nov 2022, Published online: 09 Dec 2022
 

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Additional information

Funding

HP has within the last 3 years received research grants from Pfizer and Merck. AU has within the last 3 years received research grants from Merck.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.